ELAB · PMGC Holdings Inc. Common Stock
View on chartInsiders & Stakes
| Braeden Lichti Director | ▲ Buy | Grant | 3,336,437 Shares held | 3/26/2025 | View profile |
| Bensler Graydon CEO & CFO | ▲ Buy | Grant | 3,036,437 Shares held | 3/26/2025 | View profile |
| BWL Investments Ltd. 10% Owner | ▼ Sell | Other | 1,967,965 Shares held | 12/28/2023 | View profile |
Transaction History
| Bensler Graydon | ▲ Buy | Grant | 3,036,437 | $0 | 3/26/2025 |
| Braeden Lichti | ▲ Buy | Grant | 3,336,437 | $0 | 3/26/2025 |
| BWL Investments Ltd. | ▼ Sell | Other | 828,000 | $0 | 12/28/2023 |
| BWL Investments Ltd. | ▼ Sell | Other | 828,000 | $0 | 12/28/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
PMGC Holdings Completes $100M SPAC IPO, Launches NorthStrive
PMGC Holdings has completed a $100 million SPAC IPO, launching NorthStrive Acquisition Corp. I as the first in a planned series to expand its M&A strategy. Additionally, its subsidiary NorthStrive Biosciences has partnered with Charles River Laboratories to conduct analytical characterization for its EL-22 and EL-32 engineered probiotic programs. These moves signal a shift toward corporate expansion and advanced development partnerships for the company.
PMGC Holdings Completes $100M SPAC IPO, Launches NorthStrive. PMGC Holdings has completed a $100 million SPAC IPO, launching NorthStrive Acquisition Corp. I as the first in a planned series to expand its M&A strategy. Additionally, its subsidiary NorthStrive Biosciences has partnered with Charles River Laboratories to conduct analytical characterization for its EL-22 and EL-32 engineered probiotic programs. These moves signal a shift toward corporate expansion and advanced development partnerships for the company.